

Generic Name: Axitinib**Therapeutic Class or Brand Name:** Inlyta®**Applicable Drugs (if Therapeutic Class):** N/A**Preferred:** N/A**Non-preferred:** N/A**Date of Origin:** 2/1/2013**Date Last Reviewed / Revised:** 9/5/2023

PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I through V are met)

- I. Documented diagnosis of renal cell carcinoma (RCC) and meets one of the following criteria:
 - A. Inlyta® is used as a first line agent in combination with avelumab OR pembrolizumab.
 - B. Inlyta® is used a single agent after failure of one prior systemic therapy.
- II. Minimum age requirement: 18 years old.
- III. Treatment must be prescribed by or in consultation with an oncologist.
- IV. Request is for a medication with the appropriate FDA labeling, or its use is supported by current clinical practice guidelines.
- V. Refer to plan document for the list of preferred products. If requested agent is not listed as a preferred product, must have a documented failure, intolerance, or contraindication to the preferred product(s).

EXCLUSION CRITERIA

- N/A

OTHER CRITERIA

- N/A

QUANTITY / DAYS SUPPLY RESTRICTIONS

- Doses are limited to 10mg twice a day. The quantity is limited to a maximum of a 30 day supply per fill.

APPROVAL LENGTH

- **Authorization:** 1 year
- **Re-Authorization:** An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective.

APPENDIX

N/A

REFERENCES

1. Inlyta. Prescribing information. Pfizer Inc; 2022. Accessed September 5, 2023 .
<http://labeling.pfizer.com/ShowLabeling.aspx?id=759>.
2. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer V.3.2023. Updated September 22, 2022. Accessed November 28, 2022.
https://www.nccn.org/professionals/physician_gls/pdf/kidney_blocks.pdf.

DISCLAIMER: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.